Peer-Reviewed Article on Neogenix Oncology® Diagnostic for Detection of Colorectal and Pancreatic Cancer Published in Jour

ROCKVILLE, Md.--(BUSINESS WIRE)-- An article on the development and efficacy of Neogenix Oncology’s new serum ELISA for the detection of colorectal and pancreatic cancer has been published in The Journal of Biomedicine and Biotechnology. The serum biomarker uses a novel chimeric antibody, NPC-1C (Ensituximab), that is the sole property of Neogenix Oncology.

In the article, entitled “Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C Antigen) From Normal MUC5AC”—authors Janos Luka, Philip M. Arlen and Andrew Bristol present study data that indicate the company’s biomarker assay detects colorectal and pancreatic cancer with a high degree of sensitivity and specificity. This offers the promise of earlier large-scale non-invasive diagnostic screening which may significantly improve clinical outcomes.

“It is gratifying to be accepted for publication by such a well regarded peer-reviewed journal,” says Philip M. Arlen, MD, the President and CEO of Neogenix Oncology. “This further validates the scientifically rigorous and sound work we are doing at Neogenix Oncology, and reinforces our commitment to helping patients who face colorectal or pancreatic cancer, two of our most devastating diseases.”

The article, which will appear in a Spring issue of the Journal of Biomedicine and Biotechnology, is already available online and can be accessed through the following link:

About Neogenix Oncology

Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of ensituximab (NPC-1C antibody) in patients with metastatic pancreatic and colorectal cancer. For more information, please visit the company’s web site at

Forward Looking Statements

Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company’s SEC reports, including the company’s Form 10 and quarterly reports on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


RMT PR Management
RoseMarie Terenzio, 212-414-1909
C: 917-913-7226
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  General Health